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Background and Purpose  Epilepsy is a chronic neurological disease that represents a tre-
mendous burden on both patients and society in general. Studies have addressed how demo-
graphic variables, socioeconomic variables, and psychological comorbidity are related to the 
quality of life (QOL) of people with epilepsy (PWE). However, there has been less focus on how 
these factors may differ between patients who exhibit varying degrees of seizure control. This 
study utilized data from the Managing Epilepsy Well (MEW) Network of the Centers for Dis-
ease Control and Prevention with the aim of elucidating differences in demographic variables, 
depression, and QOL between adult PWE.
Methods  Demographic variables, depression, and QOL were compared between PWE who 
experience clinically relevant differences in seizure occurrence.
Results  Gender, ethnicity, race, education, income, and relationship status did not differ sig-
nificantly between the seizure-frequency categories (p>0.05). People with worse seizure control 
were significantly younger (p=0.039), more depressed (as assessed using the Patient Health 
Questionnaire) (p=0.036), and had lower QOL (as determined using the 10-item Quality of Life 
in Epilepsy for Adults scale) (p<0.001).
Conclusions  The present results underscore the importance of early screening, detection, and 
treatment of depression, since these factors relate to both seizure occurrence and QOL in PWE.
Key Words   epilepsy, seizure frequency, depression, quality of life, self-management.
Demographic and Clinical Correlates of Seizure Frequency: 
Findings from the Managing Epilepsy Well  
Network Database
INTRODUCTION
Epilepsy is a chronic debilitating condition that affects about 2.9 million people in the Unit-
ed States.1 The disorder represents a tremendous burden on both individuals and society, 
with estimates of a direct cost of USD 4.3 billion and a total cost of USD 9.6–15.5 billion an-
nually.2,3 Although the disease is characterized by episodic attacks, unpredictable recurrent 
seizures in people with epilepsy (PWE) cause significant disability and negatively impact 
their health, productivity, and activities of daily living.4,5 Further, the disease has substantial 
psychosocial, behavioral, and cognitive sequelae, with frequent seizures, stigma, and seizure 
worry associated with reduced quality of life (QOL).6-8 Requirements for chronic medication, 
barriers to care, employment limitations, and inability to drive a motor vehicle represent long-
term hindrances for PWE. 
Numerous studies have addressed the impact of demographic and socioeconomic vari-
ables, seizure frequency, and comorbid depression on health-related QOL in PWE,9-14 but 
there has been less research into how these factors may differ among PWE who have varying 
clinically relevant degrees of seizure control (i.e., completely controlled, occasional seizures, 
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or poorly controlled). Reports on factors affecting seizure 
frequency in PWE have typically focused on pharmacologi-
cal treatments15 or outcomes of epilepsy surgery.16 Since PWE 
are a heterogeneous population in which the frequency of sei-
zures may vary significantly between individuals and seizure 
control is a major therapeutic objective, there is value in iden-
tifying differences in demographic and clinical variables be-
tween PWE with varying seizure frequencies. 
The primary purpose of this study was to elucidate differ-
ences in demographic variables, depression, and QOL be-
tween PWE stratified by seizure frequency in a non-surgical 
sample of adult PWE using aggregate, de-identified data ob-
tained in studies conducted at multiple United States institu-
tions coordinated by the Managing Epilepsy Well (MEW) 
Network of the Centers for Disease Control and Prevention 
(https://www.cdc.gov/epilepsy/research/MEW-network.htm 
and http://www.managingepilepsywell.org). The present study 
additionally aimed to demonstrate the validity of using the 
MEW Network Database (MEW-DB) to conduct research on 
epilepsy. The MEW-DB is a harmonized database that includes 
de-identified data obtained in studies of self-management in 
PWE. The MEW-DB was used to compare the variables of inter-
est between PWE in the following three clinically relevant 
groups categorized based on the seizure frequency during the 
past 30 days: completely seizure-free (SZF); fair seizure control, 
with one to four seizures (FC); and poor seizure control, with at 
least five seizures (PC). 
METHODS
This cross-sectional analysis used data from 481 PWE en-
rolled in 6 MEW Network epilepsy self-management studies. 
A detailed description of the MEW Network is available else-
where.17 The MEW-DB was developed to facilitate aggregate 
secondary analyses of data collected at individual MEW Net-
work sites,18 with approval received from the Institutional 
Review Board of University Hospitals Cleveland Medical 
Center (Principal Investigator, Martha Sajatovic; Reference 
no. 068620). The de-identified data reported here were col-
lected across four U.S. institutions using studies performed 
from 2007 to 2016 and reports on baseline data only. The ag-
gregate data used in the analysis comprised participant data 
from the HOBSCOTCH (HOme-Based Self-management 
and Cognitive Training CHanges lives) clinical trial performed 
at Dartmouth-Hitchcock Medical Center,19 the WebEase (Web 
Epilepsy Awareness Support and Education) clinical trial per-
formed at Emory University,20 the FOCUS (Figure out the 
problem or the issue, Observe your routine, Connect your 
observations and choose a change goal, Undertake a change 
strategy, and Study the results) on Epilepsy pilot study and 
randomized controlled trial performed at the University of 
Michigan, and the TIME (Targeted Self-Management for Epi-
lepsy and serious mental illness) and SMART (Self-manage-
ment for people with epilepsy and a history of negative health 
events) clinical trials performed at Case Western Reserve Uni-
versity. All of the included individuals were at least 18 years 
old and had a self-reported diagnosis of epilepsy. They pro-
vided informed consent for participating in the respective 
studies and the values of demographic variables including 
age, gender, race, ethnicity, education, income, and relation-
ship status. The study participants also provided information 
on seizure frequency and were assessed for QOL and depres-
sion severity. Seizure frequency was standardized across stud-
ies to a consistent time frame of 30 days prior to presentation 
for the baseline study assessment. Data on seizure type and 
epilepsy type were not consistently available across the includ-
ed studies. The patients were classified based on the 30-day sei-
zure count into SZF, FC, and PC groups. 
Quality-of-life assessment
QOL in this study was measured with the 10-item Quality of 
Life in Epilepsy for Adults scale (QOLIE-10). The QOLIE-10 
is an extensively validated survey of health-related QOL that 
covers both general and epilepsy-specific domains.21 It is used 
by clinicians and researchers in various settings and languag-
es, and is a screening version derived from 2 longer instru-
ments: the 89-item QOLIE-89 and the 31-item QOLIE-31. 
The QOLIE-10 assessment includes questions on health, dai-
ly activities, and distress related to epilepsy. Total scores on the 
QOLIE-10 range from 1 to 50, with lower scores indicating 
better QOL. To accommodate missing data in the pooled 
MEW-DB sample, the total score for QOLIE-10 was calculated 
as the sum of scores for all questions divided by the number of 
questions answered and a score range of 1–5 with lower scores 
indicating better QOL. Previous studies have investigated the 
correlations between QOLIE-10 scores and health-care utili-
zation,22 satisfaction with care,23 anxiety,8 and depression.8
Mental health assessment
Depression in this study was quantified with the nine-item Pa-
tient Health Questionnaire (PHQ-9), which is a self-adminis-
tered multipurpose instrument for screening, measuring, and 
monitoring the severity of depression in patients. The PHQ-9 
has been validated in several patient populations,24 including 
adult PWE,25 and it incorporates the Diagnostic and Statistical 
Manual of Mental Disorders-5 diagnostic criteria for major 
depressive disorder in patients with medical comorbidities. In 
PWE, the PHQ-9 has been validated against the Neurologi-
cal Disorders Depression Inventory for Epilepsy25 and has 
been used in several studies.26,27 Scores on the PHQ-9 of 5, 10, 
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15, and 20 correspond to mild, moderate, moderately severe, 
and severe depression, respectively. 
Statistical analysis
Data were analyzed using the Statistical Package for the So-
cial Sciences (SPSS) program (version 22, IBM SPSS Statistics 
for Windows, IBM Corporation, Armonk, NY, USA). Due to 
heterogeneity in variable definitions and data collection be-
tween the 4 study sites contributing data, the sample sizes 
used when comparing the demographic variables and health 
status measures between the 3 clinically relevant seizure-fre-
quency groups (SZF, FC, and PC) differed between variables, 
ranging from 481 for age to 230 for relationship status (Table 1). 
Chi-square tests were used to compare the categorical vari-
ables of gender, race, ethnicity, education, income, and rela-
tionship status. One-way ANOVA was applied to identify sig-
nificant intergroup differences in the continuous variables of 
age, PHQ-9 score, and QOLIE-10 score. A post-hoc analysis 
of differences between groups was conducted using Tukey’s 
honest-significant-difference test. In addition to evaluating 
the three clinically relevant seizure-frequency subgroups, de-
mographic variables and clinical correlates of the 30-day sei-
zure frequency as a continuous measure were evaluated us-
ing Spearman’s or Pearson’s correlation for continuous clinical 
Table 1. Comparison of baseline demographic and clinical variables stratified by 30-day seizure frequency among adult patients with epilepsy in 






One to four recent 
seizures (n=188)




Age, years (n=481) 42.8±13.0 44.6±13.7 42.7±12.8 40.0±11.8 0.039
Gender (n=480)
Male 157 (32.7) 65 (39.2) 58 (30.9) 21 (28.4) 0.147
Female 323 (67.3) 101 (60.8) 130 (69.1) 53 (71.6)
Ethnicity (n=272) 
HOBSCOTCH not included
Hispanic/Latino 25 (9.2) 10 (11.4) 10 (9.1) 1 (3.0) 0.365
Not Hispanic/Latino 247 (90.8) 78 (88.6) 100 (90.9) 32 (97.0)
Race (n=405) 
HOBSCOTCH not included
White 306 (75.6) 102 (73.9) 120 (76.4) 54 (80.6) 0.733
Black/African-American 72 (17.8) 29 (21.0) 27 (17.2) 9 (13.4)  
Other 27 (6.6) 7 (5.1) 10 (6.4) 4 (6.0)
Social variables    
Education (n=476)
Up to high-school graduate 107 (22.5) 32 (19.3) 46 (24.7) 13 (17.8) 0.328
At least college 369 (77.5) 134 (80.7) 140 (75.3) 60 (82.2)
Income (n=232) 
HOBSCOTCH & WebEase not included
Less than USD 25,000 148 (63.8) 49 (59.8) 53 (60.2) 21 (72.4) 0.514
USD 25,000–49,999 33 (14.2) 16 (19.5) 13 (14.8) 2 (6.9)
At least USD 50,000 51 (22.0) 17 (20.7) 22 (25.0) 6 (20.7)
Relationship status (n=230) 
HOBSCOTCH & FOCUS not included
Married/partnered 93 (40.4) 30 (32.3) 35 (42.2) 21 (51.2) 0.098
Other 137 (59.6) 63 (67.7) 48 (57.8) 20 (48.8)
PHQ-9* (n=331)
WebEase not included 8.9±6.2 7.6±5.4 9.4±6.4 9.8±7.0 0.036
QOLIE-10† (n=415)
HOBSCOTCH not included 2.9±0.9 2.5±0.8 3.1±0.9 3.2±0.7 <0.001
Data are n (%) or mean±standard-deviation values.
*Lower scores indicate less-severe depression, †Lower scores indicate better quality of life.
FOCUS: Figure out the problem or the issue, Observe your routine, Connect your observations and choose a change goal, Undertake a change strategy, 
and Study the results, HOBSCOTCH: HOme-Based Self-management and Cognitive Training CHanges lives, PHQ-9: nine-item Patient Health Question-
naire, QOLIE-10: 10-item Quality of Life in Epilepsy for Adults scale, WebEase: Web Epilepsy Awareness Support and Education.
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measures (i.e., age, PHQ-9, QOLIE-10), and t-tests, Kruskal-
Wallis tests, or Mann-Whitney tests for categorical clinical 
measures. The cutoff for statistical significance in this study 
was set at p≤0.05. 
RESULTS
The demographic and clinical variables of the entire sample 
and the three seizure-frequency categories are summarized 
and compared in Table 1. The participants were aged 42.8± 
13.0 years (mean±standard deviation, n=481). Of the 480 
participants who reported gender, 157 (32.7%) of them were 
male and 323 (67.3%) were female. Of the 272 participants 
who reported ethnicity, 25 (9.2%) identified as Hispanic. Of 
the 405 participants who reported their race, 72 (17.8%) were 
African-American. The sample of PWE for whom data on 
education were available comprised 476 individuals, 369 
(77.5%) of whom were college educated. As for income, out 
of 232 included PWE, 148 (63.8%) reported annual earnings 
of less than USD 25,000, 33 (14.2%) earned USD 25,000– 
49,999, and 51 (22.0%) had incomes of at least USD 50,000. In 
terms of marital or relationship status, 93 out of 230 (40.4%) 
PWE reported being married or partnered. The PHQ-9 score 
in 331 PWE was 8.9±6.2, and the QOLIE-10 score in 415 
PWE was 2.9±0.9.
Gender, ethnicity, race, education, income, and relation-
ship status did not differ significantly between PWE in the 
SZF, FC, and PC groups. Patients with worse seizure control 
were younger (p<0.039), significantly more depressed (p= 
0.036), and had a lower QOL (p<0.001). Those in the SZF, FC, 
and PC groups were aged 44.6±13.7, 42.7±12.8, and 40.0± 
11.8 years, respectively (p=0.039); their PHQ-9 scores were 
7.6±5.4, 9.4±6.4, and 9.8±7.0 (p=0.036), and their QOLIE-10 
scores were 2.5±0.8, 3.1±0.9, and 3.2±0.7 (p<0.001) (Fig. 1).
Our evaluation of the relationship between the past 30-
day seizure frequency as a continuous measure (irrespective 
of the clinically relevant degree of seizure control) revealed 
that PHQ-9 and QOLIE-10 scores remained significantly 
correlated (rho=0.19 and p=0.001, and rho=0.381 and p< 
0.001, respectively). Greater number of seizures was associat-
ed with worse depression severity and lower QOL. Age was 
not significantly correlated with 30-day seizure frequency 
(rho=-0.02, p=0.67). With respect to categorical demo-
graphic variables, we found that 30-day seizure frequency as 
a continuous variable was significantly correlated with gen-
der (p=0.047) but not with the other demographic variables.
DISCUSSION
This study found that PWE with different clinically relevant 
degrees of seizure control generally have similar demo-
graphic characteristics. However, evidence was found of sig-
nificant differences in depression and QOL in PWE, with 
frequent seizures associated with an increased severity of de-
pression and lower QOL. Notably, the PHQ-9 and QOLIE-10 
scores did not differ significantly between the FC and PC 
groups, but they were significantly different in the SZF group, 
suggesting that experiencing a seizure over a 30-day period is 
associated with worse QOL in PWE. This underscores the 
importance of achieving complete seizure freedom for ame-
liorating depression and improving the QOL in this patient 
population. 
The cross-sectional design of this study means that causal 
inferences cannot be made, but the elucidated relationship 
between seizure frequency and QOL is congruous with the 
results of numerous published multivariate analyses of QOL 
correlates in PWE. Other studies have shown that both de-
pression11,12 and seizure frequency10,12-14 are correlated with 
reduced QOL in PWE. Poor seizure control might precipi-
tate stress and depression, leading to reduced QOL. The con-
sistency of the present findings with those in other popula-
tions of PWE underscores the validity of using the MEW-
DB to advance original clinical research into epilepsy.



































SZF                  FC                  PCC  
Fig. 1. Age and QOLIE-10 and PHQ-9 scores among adult patients with epilepsy enrolled in Managing Epilepsy Well Network studies. A: Age. B: Total 
PHQ-9 score. C: QOLIE-10 score. Data are mean and standard-deviation values. *p value significant at p≤0.05, †p value significant at p≤0.01. FC: one to 
four recent seizures, PC: at least five recent seizures, PHQ-9: nine-item Patient Health Questionnaire (lower scores indicate less severe depression 
symptoms), QOLIE-10: 10-item Quality of Life in Epilepsy for Adults scale (lower scores indicate better quality of life), SZF: no recent seizures.
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seizure frequency in the three frequency categories of PWE 
might reflect how chronic illness is managed. Learning to 
manage epilepsy takes time and practice, as supported by a 
recent prospective study of seizure recurrence in PWE treat-
ed with antiepileptic monotherapy finding older age to be 
associated with a lower likelihood of seizure at follow-up.28 
Additionally, Escoffery et al.29 found that safety, wellness, and 
treatment behaviors were performed less by younger PWE 
(<30 years) compared to those in older age groups. However, 
our analysis of the 30-day seizure frequency as a continuous 
measure in relation to demographic variables did not show a 
significant relationship with age. These discrepancies might 
have been due to our sample being relatively small, with limited 
numbers of individuals at the upper and lower extremes of 
age. 
The lack of significant differences in other demographic 
variables such as education and income between the SZF 
group and the FC and PC groups suggests that these factors 
may be more affected by the affective and cognitive sequelae 
of epilepsy than by the frequency of seizures.30 Since the mor-
tality, morbidity, and long-term prognosis in chronic disease 
are negatively impacted by the presence of affective disor-
ders, depression can be conceptualized as a modifiable factor 
in seizure frequency and QOL outcomes in epilepsy. Comor-
bid depression has been shown to cause poor medication ad-
herence,31 which in PWE can increase the frequency and se-
verity seizures and decrease QOL. A significant association 
has been shown between seizure frequency and QOL across 
all subscale domains of the QOLIE-31 assessment: seizure 
worry, overall QOL, emotional well-being, energy/fatigue, cog-
nitive functioning, medication effect, and social functioning.9 
The rate of psychiatric illness is higher in PWE than in the gen-
eral population and those affected by other forms of chronic 
illness.32,33 
Our findings underscore the importance of the timely 
identification of comorbid depression by applying screening 
tools such as the PHQ-9, with subsequent behavioral therapy 
and/or pharmacological management being applied where 
required. The benefit of early depression screening, detec-
tion, and treatment in PWE has been demonstrated by other 
investigators. In a randomized controlled trial of systemic 
family therapy in younger PWE and comorbid depression 
and anxiety, Li et al.34 found that therapy significantly re-
duced the 30-day seizure frequency as well as the depression 
and anxiety symptoms.
Several MEW Network interventions specifically target the 
reduction of depression as a modifiable and important out-
come in epilepsy self-management.35 The UPLIFT (Using 
Practice and Learning to Increase Favorable Thoughts) for 
Prevention program tested a remotely delivered self-manage-
ment intervention for PWE with mild symptoms of depres-
sion. The trial demonstrated that the incidence of new or re-
lapsing depressive episodes was significantly lower in the 
intervention group than in the controls.36 These results sup-
plemented those from a previous single-site trial of UPLIFT 
for Treatment.37 In another MEW Network study, Ciecha-
nowski et al.38 implemented the Program to Encourage Active, 
Rewarding Lives for Seniors (PEARLS), an evidence-based 
treatment program for depression in older adults and PWE.39 
Adults participating in the PEARLS program exhibited signif-
icantly lower severities of depression and suicidal ideation.38,39 
The recently published TIME study targeting PWE with co-
morbid severe mental illnesses including severe depression, 
schizophrenia, and bipolar disorder found that TIME was as-
sociated with improved depression severity compared to the 
standard treatment.40 
Limitations of the present study include its cross-sectional 
design and the self-reporting of data from heterogeneous 
sources, which led to inconsistencies in the sample sizes and 
in the various demographic and clinical variables analyzed 
between the included studies. Additionally, the education lev-
el of the included participants was on average higher than 
the typical level in large studies of PWE. However, at least half 
of the study participants were from lower income households. 
The higher level of education might reflect selection bias in 
PWE who enroll in self-management research. The high prev-
alence of moderate depression also reflects selection bias for 
study participation. 
The continuing expansion and refinement of the MEW-DB 
will led to future analyses aimed at characterizing the longitu-
dinal outcomes for variations in seizure frequency, mood, and 
other health outcomes among individuals with a chronic neu-
rological condition. 
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